GSK (GSK)
| Bid | 36.61 |
| Market Cap | 74.72B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 1.55 |
| PE Ratio (ttm) | 23.62 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 36.97 |
| Volume | 3,838,256 |
| Avg. Volume (20D) | 4,491,508 |
| Open | 36.59 |
| Previous Close | 36.17 |
| Day's Range | 36.47 - 36.84 |
| 52-Week Range | 31.72 - 45.93 |
| Beta | undefined |
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines ...
Analyst Forecast
According to 4 analyst ratings, the average rating for GSK stock is "Hold." The 12-month stock price forecast is $47, which is an increase of 28.36% from the latest price.
20 hours ago · accessnewswire.com
Levi & Korsinsky Notifies GSK plc Investors of a Class Action Lawsuit and Upcoming Deadline - GSKNEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow...
